The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
Open accessAbstract
Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of ibrutinib, a first-generation BTK inhibitor, with zanubrutinib, a novel highly selective BTK inhibitor, in patients with WM. Patients with MYD88L265P disease were randomly assigned 1:1 to treatment with ibrutinib or zanubrutinib. The primary end point was the proportion of patients achieving a complete response (CR) or a very good partial response (VGPR) by independent review. Key secondary end points included major response rate (MRR), progression-free survival (PFS), duration of response (DOR), disease burden, and safety. A total of 201 patients were randomized, and 199 received ≥1 dose of study treatment. No patient achieved a CR. Twenty-nine (28%) zanubrutinib patients and 19 (19%) ibrutinib patients achieved a VGPR, a nonstatistically significant difference (P = .09). MRRs were 77% and 78%, respectively. Median DOR and PFS were not reached; 84% and 85% of ibrutinib and zanubrutinib patients were progression free at 18 months. Atrial fibrillation, contusion, diarrhea, peripheral edema, hemorrhage, muscle spasms, and pneumonia, as well as adverse events leading to treatment discontinuation, were less common among zanubrutinib recipients. Incidence of neutropenia was higher with zanubrutinib, although grade ≥3 infection rates were similar in both arms (1.2 and 1.1 events per 100 person-months). These results demonstrate that zanubrutinib and ibrutinib are highly effective in the treatment of WM, but zanubrutinib treatment was associated with a trend toward better response quality and less toxicity, particularly cardiovascular toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Treon, S. P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Sheehy, P., Manning, R. J., Patterson, C. J., Tripsas, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200710 · Cited by 1,294
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
Treon, S. P., Tripsas, C. K., Meid, K., Warren, D., Varma, G., Green, R., Argyropoulos, K. V., Yang, G., Cao, Y., Xu, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501548 · Cited by 942
Self-citationA Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Role of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
Hunter, Z. R., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Manning, R. J., Tripsas, C., Patterson, C. J., Sheehy, P., et al. (2014) · Blood · doi:10.1182/blood-2013-09-525808 · Cited by 488
International prognostic scoring system for Waldenström macroglobulinemia
Morel, P., Duhamel, A., Gobbi, P., Dimopoulos, M. A., Dhodapkar, M. V., McCoy, J., Crowley, J., Ocio, E. M., Garcia-Sanz, R., Treon, S. P., et al. (2009) · Blood · doi:10.1182/blood-2008-08-174961 · Cited by 416
Self-citationTam, C. S., Trotman, J., Opat, S., Burger, J. A., Cull, G., Gottlieb, D., Harrup, R., Johnston, P. B., Marlton, P., Munoz, J., et al. (2019) · Blood · doi:10.1182/blood.2019001160 · Cited by 361
Self-citationPhase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
Dimopoulos, M. A., Tedeschi, A., Trotman, J., García-Sanz, R., Macdonald, D., Leblond, V., Mahe, B., Herbaux, C., Tam, C., Orsucci, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802917 · Cited by 357
Self-citationIbrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Levade, M., David, E., Garcia, C., Laurent, P.-A., Cadot, S., Michallet, A.-S., Bordet, J.-C., Tam, C., Sié, P., Ysebaert, L., et al. (2014) · Blood · doi:10.1182/blood-2014-06-583294 · Cited by 321
Self-citationIbrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies
Shatzel, J. J., Olson, S. R., Tao, D. L., McCarty, O. J. T., Danilov, A. V., & DeLoughery, T. G. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13651 · Cited by 279
Brown, J. R., Moslehi, J., O’Brien, S., Ghia, P., Hillmen, P., Cymbalista, F., Shanafelt, T. D., Fraser, G., Rule, S., Kipps, T. J., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.171041 · Cited by 267
Self-citationHypertension and incident cardiovascular events following ibrutinib initiation
Dickerson, T., Wiczer, T., Waller, A., Philippon, J., Porter, K., Haddad, D., Guha, A., Rogers, K. A., Bhat, S., Byrd, J. C., et al. (2019) · Blood · doi:10.1182/blood.2019000840 · Cited by 260
Dimopoulos, M. A., Trotman, J., Tedeschi, A., Matous, J. V., Macdonald, D., Tam, C., Tournilhac, O., Ma, S., Oriol, A., Heffner, L. T., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30632-5 · Cited by 240
Self-citationIbrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
Kamel, S., Horton, L., Ysebaert, L., Levade, M., Burbury, K., Tan, S., Cole-Sinclair, M., Reynolds, J., Filshie, R., Schischka, S., et al. (2015) · Leukemia · doi:10.1038/leu.2014.247 · Cited by 231
Self-citationCao, Y., Hunter, Z. R., Liu, X., Xu, L., Yang, G., Chen, J., Patterson, C. J., Tsakmaklis, N., Kanan, S., Rodig, S., et al. (2015) · Leukemia · doi:10.1038/leu.2014.187 · Cited by 227
Self-citationRoccaro, A. M., Sacco, A., Jimenez, C., Maiso, P., Moschetta, M., Mishima, Y., Aljawai, Y., Sahin, I., Kuhne, M., Cardarelli, P., et al. (2014) · Blood · doi:10.1182/blood-2014-03-564583 · Cited by 207
A Report on the Natural Duration of Cancer.
(1927) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1927.02680330059037 · Cited by 207
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
Treon, S. P., Gustine, J., Meid, K., Yang, G., Xu, L., Liu, X., Demos, M., Kofides, A., Tsakmaklis, N., Chen, J. G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.6426 · Cited by 182
Self-citationDimopoulos, M. A., Kastritis, E., Owen, R. G., Kyle, R. A., Landgren, O., Morra, E., Leleu, X., García-Sanz, R., Munshi, N., Anderson, K. C., et al. (2014) · Blood · doi:10.1182/blood-2014-03-565135 · Cited by 169
Self-citationOwen, R. G., McCarthy, H., Rule, S., D'Sa, S., Thomas, S. K., Tournilhac, O., Forconi, F., Kersten, M. J., Zinzani, P. L., Iyengar, S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30210-8 · Cited by 167
Self-citationIncidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
de Weerdt, I., Koopmans, S. M., Kater, A. P., & van Gelder, M. (2017) · Haematologica · doi:10.3324/haematol.2017.164103 · Cited by 147
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
Yang, G., Buhrlage, S. J., Tan, L., Liu, X., Chen, J., Xu, L., Tsakmaklis, N., Chen, J. G., Patterson, C. J., Brown, J. R., et al. (2016) · Blood · doi:10.1182/blood-2016-01-695098 · Cited by 135
Self-citationCao, Y., Hunter, Z. R., Liu, X., Xu, L., Yang, G., Chen, J., Tsakmaklis, N., Kanan, S., Castillo, J. J., & Treon, S. P. (2014) · British Journal of Haematology · doi:10.1111/bjh.13200 · Cited by 109
Self-citationWaldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management
Gertz, M. A. (2018) · American Journal of Hematology · doi:10.1002/ajh.25292 · Cited by 77
Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors
Tang, C. P. S., McMullen, J. R., & Tam, C. S. L. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1375110 · Cited by 71
Self-citationAtrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia
Gustine, J. N., Meid, K., Dubeau, T. E., Treon, S. P., & Castillo, J. J. (2016) · American Journal of Hematology · doi:10.1002/ajh.24366 · Cited by 59
Self-citationIbrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes
Shafaattalab, S., Lin, E. C., Christidi, E., Huang, H., Nartiss, Y., Garcia, A., Lee, J., Protze, S. I., Keller, G. M., Brunham, L. R., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.03.011 · Cited by 54
On the variance estimator for the Mantel-Haenszel risk difference
Sato, T. S. (1989) · Biometrics · Cited by 36
Cited by
Byrd, J. C., Hillmen, P., Ghia, P., Kater, A. P., Chanan-Khan, A., Furman, R. R., O'Brien, S., Yenerel, M. N., Illés, A., Kay, N., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01210 · Cited by 669
Self-citationZanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Zhou, K., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211582 · Cited by 489
Self-citationTam, C. S., Brown, J. R., Kahl, B. S., Ghia, P., Giannopoulos, K., Jurczak, W., Šimkovič, M., Shadman, M., Österborg, A., Laurenti, L., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00293-5 · Cited by 291
Self-citationComparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
Estupiñán, H. Y., Berglöf, A., Zain, R., & Smith, C. I. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630942 · Cited by 267
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Wen, T., Wang, J., Shi, Y., Qian, H., & Liu, P. (2021) · Leukemia · doi:10.1038/s41375-020-01072-6 · Cited by 262
Metadata
- Authors
- Tam, C. S., Opat, S., D'Sa, S., Jurczak, W., Lee, H.-P., Cull, G., Owen, R. G., Marlton, P., Wahlin, B. E., Sanz, R. G., McCarthy, H., Mulligan, S., Tedeschi, A., Castillo, J. J., Czyz, J., Fernández de Larrea, C., Belada, D., Libby, E., Matous, J. V., Motta, M., Siddiqi, T., Tani, M., Trneny, M., Minnema, M. C., Buske, C., Leblond, V., Trotman, J., Chan, W. Y., Schneider, J., Ro, S., Cohen, A., Huang, J., & Dimopoulos, M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2020-10-29
- Volume
- 136
- Issue
- 18
- Pages
- 2038-2050
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3046825703
- Cited by
- 466
- References
- 31
- FWCI
- 30.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.